ENTITY

SIGA Technologies (SIGA US)

23
Analysis
Health CareUnited States
SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.
more
19 Nov 2024 07:10Issuer-paid

SIGA Technologies - Strong order book moving into Q424

SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024....

Share
24 Aug 2024 01:10Issuer-paid

SIGA Technologies - TPOXX chalks up another DoD contract win

SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is...

Share
19 Aug 2024 19:10Issuer-paid

SIGA Technologies - PALM 007 data warrant a closer look in mpox

Although the topline results of PALM 007 (studying SIGA’s tecovirimat in the treatment of mpox) did not meet the statistical significance for the...

Share
05 Aug 2024 19:10Issuer-paid

SIGA Technologies - Momentum building as the year progresses

SIGA Technologies had another strong quarter in Q224, driven by intravenous TPOXX (IVT) deliveries to the Strategic National Stockpile (SNS) and...

Share
14 May 2024 07:10Issuer-paid

SIGA Technologies - Optimizing the TPOXX value proposition

SIGA’s Q124 results were marked by material BARDA and international TPOXX deliveries and highlighted the company’s strategic push towards...

Share
x